전문 번역가, 번역 회사, 웹 페이지 및 자유롭게 사용할 수 있는 번역 저장소 등을 활용합니다.
eular response (%)
eular vastus (%)
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
response
vastus
마지막 업데이트: 2017-04-26
사용 빈도: 10
품질:
& response
& vasta
마지막 업데이트: 2011-10-23
사용 빈도: 1
품질:
경고: 보이지 않는 HTML 형식이 포함되어 있습니다
response rate
ravivastuse määr
마지막 업데이트: 2017-04-26
사용 빈도: 3
품질:
response duration
ravivastuse kestus
마지막 업데이트: 2017-04-26
사용 빈도: 3
품질:
written response.
kirjalik vastus.
마지막 업데이트: 2018-02-21
사용 빈도: 1
품질:
haematological response (%)
hematoloogiline ravivastus (%)
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
eular good/ moderate
eular hea/ mõõdukas
마지막 업데이트: 2012-04-11
사용 빈도: 4
품질:
acr/eular index remission, n (%)
acr/eular indeksipõhine remissioon, n (%)
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
week 24: acr/eular boolean remission, n (%)
nädal 24: acr/eular boole’i remissioon, n (%)
마지막 업데이트: 2017-04-26
사용 빈도: 2
품질:
a good to moderate european league against rheumatism (eular) response was achieved by significantly more rituximab treated patients compared to patients treated with methotrexate alone (table 9).
hea kuni mõõduka euroopa reumavastase liiga (eular) vastuse saavutas oluliselt rohkem rituksimabiga kui ainult metotreksaadiga ravitud patsiente (tabel 9).
마지막 업데이트: 2012-04-11
사용 빈도: 2
품질:
similarly, a good to moderate european league against rheumatism (eular) response was achieved by significantly more mabthera treated patients treated with mabthera and methotrexate compared to patients treated with methotrexate alone (table 10).
sarnaselt saavutas kõikides uuringutes hea kuni mõõduka euroopa reumavastase liiga (eular) vastuse saavutas oluliselt rohkem mabthera’t ja metotreksaati saanud kui ainult metotreksaadiga ravitud patsiente (tabel 10).
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
similarly, in all studies a good to moderate european league against rheumatism (eular) response was achieved by significantly more mabthera treated patients treated with mabthera and methotrexate compared to patients treated with methotrexate alone (table 10).
sarnaselt saavutas kõikides uuringutes hea kuni mõõduka euroopa reumavastase liiga (eular) vastuse saavutas oluliselt rohkem mabthera’t ja metotreksaati saanud kui ainult metotreksaadiga ravitud patsiente (tabel 10).
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
in this study, acr/eular remission (boolean and index) were also analysed as pre-specified exploratory endpoints, with higher responses observed in the tocilizumab groups.
selles uuringus analüüsiti ettemääratud uurivate tulemusnäitajatena ka acr/eular remissiooni (boole’i ja indeksipõhine remissioon), mille saavutamise määr oli suurem totsilizumabi rühmades.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질: